Related Experiment Videos
[Diclonate P in rheumatoid arthritis]
Terapevticheskii Arkhiv
|January 1, 1994
Summary
Diclonate P, a sodium diclofenac formulation, effectively treated rheumatoid arthritis patients. It demonstrated significant analgesic and anti-inflammatory benefits with good tolerance across various dosage forms.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory condition requiring effective disease-modifying antirheumatic drugs (DMARDs).
- Sodium diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) with established analgesic and anti-inflammatory properties.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Diclonate P (sodium diclofenac) as a primary antirheumatic agent in patients with rheumatoid arthritis.
- To assess the performance of three different dosage forms of Diclonate P: tablets, suppositories, and ampoules.
Main Methods:
- A study involving 74 patients diagnosed with rheumatoid arthritis.
- Diclonate P was administered as the basic antirheumatic drug.
- Statistical analysis was employed to evaluate analgesic and anti-inflammatory activity and tolerance.
Main Results:
- Diclonate P demonstrated statistically significant analgesic and anti-inflammatory effects in RA patients.
- Good tolerance was observed across all three dosage forms (tablets, suppositories, ampoules).
- Diclonate P showed favorable comparisons with chemical analogs in certain parameters.
Conclusions:
- Diclonate P is an effective and well-tolerated treatment option for rheumatoid arthritis.
- The established efficacy and safety profile support its use as a basic antirheumatic drug.
- Diclonate P presents a competitive alternative among NSAIDs for RA management.